FLT3 and acute myeloid leukemia: On 21 September 2018, gilteritinib was approved in Japan for the treatment of R/R FLT3-mutated AML; on November 28th of the same year, the US Food and Drug Administration (FDA) also declared marketing approval of gilteritinib for the same indication as in the United States.